Although considerable advances have been made in the clinical treatment of osteosarcoma (OS), a type of bone cancer, the overall survival rate of OS patients has not significantly increased. In order to expand the choices for the clinical diagnosis and treatment of OS, it is necessary to investigate molecular mechanisms and identify novel therapeutic targets.
Using the immunohistochemistry method, researchers from the Wuming Hospital of Guangxi Medical University and the First Affiliated Hospital of Guangxi Medical University analyzed PLCE1 gene and its expression in osteosarcoma and normal bone tissue. After exploring the relationship between PLCE1 and immune genes and examining the biological function of PLCE1 in osteosarcoma, they came to a conclusion that its expression in osteosarcoma tissue was higher than that in normal bone tissue. Furthermore, assays found that PLCE1 may promote immune escape from osteosarcoma by CD70-CD27 signaling pathway. Silencing this gene brings certain behaviors of OS cells: it promotes cell death, inhibits cell growth and division, and prevents cell migration and invasion.
Based on the results, researchers concluded that PLCE1 is a poor prognostic marker and may be a potential key factor affecting the immune status of OS tumor microenvironment.
Reference: Huang L, Liao C, Wu H, Huang P. PLCE1 is a poor prognostic marker and may promote immune escape from osteosarcoma by the CD70-CD27 signaling pathway. Bosn J of Basic Med Sci [Internet]. 2022Jun.26 [cited 2022Jun.27];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/7416
Editor: Merima Bukva, MPharm